Merck Lands Late-Stage Enbrel Biosimilar In Deal With South Korea's Hanwha
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Merck & Co. has become a leader in the race to bring a low-cost version of Amgen's rheumatoid arthritis blockbuster Enbrel (etandercept) to the market after gaining rights to a late-stage biosimilar version of the biologic developed by South Korea's Hanwha Chemical Corporation
You may also be interested in...
Hanwha Biologics CEO Paul Coleman On Developing Biosimilars In Korea: An Interview With PharmAsia News (Part 2 of 2)
The former Biogen Idec exec sits down to talk about Hanwha’s biosimilars strategy and pipeline, and why its deal fell apart with Merck to develop a biosimilar of Enbrel.
Hanwha Biologics CEO Paul Coleman On Developing Biosimilars In Korea: An Interview With PharmAsia News (Part 1 of 2)
The former Biogen Idec exec sits down to talk about Hanwha’s biosimilars strategy and pipeline, and why its deal fell apart with Merck to develop a biosimilar of Enbrel.
Quick Take: Merck Terminates Enbrel Biosimilar Deal With Korea’s Hanwha
In another setback to its biosimilars aspirations, Merck ends pursuit of Hanwha’s Enbrel biosimilar.